Quinoxaline1

Quinoxaline1

SCHEMBL1394500

Nc1n[nH]c2nc3ccccc3nc12

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ TP53 P04637 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ CCNT1 O60563 1/20 0.52
▸ CDK1 P06493 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CCNB1 P14635 1/20 0.52
▸ EIF2AK2 P19525 1/20 0.52
▸ CCNA2 P20248 1/20 0.52
▸ CCNE1 P24864 1/20 0.52
▸ CDK2 P24941 1/20 0.52
▸ GSK3B P49841 1/20 0.52
▸ CDK9 P50750 1/20 0.52
▸ CDK5 Q00535 1/20 0.52
▸ CDK5R1 Q15078 1/20 0.52
▸ KDM4E B2RXH2 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoxaline1 SCHEMBL29447180 1.00 MAPT (0.52) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL5251534 0.76 CYP1A2 (0.46) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL5247702 0.73 ALDH1A1 (0.46) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL10333619 0.73 GAA (0.57) MAPTKMT2AMEN1CYP3A4CDK1
SCHEMBL29515180 0.69 MAPT (0.62) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL13856236 0.68 KMT2A (0.63) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL29444102 0.67 MAPT (1.00) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL503252 0.67 MAPT (1.00) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL29402115 0.67 MAPT (0.71) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL2246928 0.67 MAPT (0.71) MAPTKMT2AMEN1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12564610-B2 Human periventricular endothelial cell therapy for neuropsychiatric disorders THE MCLEAN HOSPITAL CORPORATION (US) 2026-03-03 — — US claimed
US-11795436-B2 Derivation of hepatic stem cells and mature liver cell types and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-10-24 — — US claimed
CN-108431209-B Derived and mature hepatocyte types of liver stem cells and uses thereof 新加坡科技研究局 2023-02-10 — — CN claimed
US-20200354683-A1 DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2020-11-12 — — US claimed
EP-3307874-A1 DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF Agency For Science, Technology And Research (SG) 2018-04-18 — — EP claimed
EP-2346988-B1 DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE JANSSEN BIOTECH INC (US) 2017-05-31 — — EP claimed
WO-2016200340-A1 DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-12-15 — — WO claimed
US-12564610-B2 Human periventricular endothelial cell therapy for neuropsychiatric disorders THE MCLEAN HOSPITAL CORPORATION (US) 2026-03-03 — — US disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 — — EP disclosed
US-20250114470-A1 THERAPY FOR POLYCYSTIC KIDNEY DISEASE UNIVERSITY OF MASSACHUSETTS 2025-04-10 — — US disclosed
WO-2025059689-A1 COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PHARYNGEAL FOREGUT ENDODERM AND ITS DERIVATIVES UNIVERSITY OF MASSACHUSETTS (US) 2025-03-20 — — WO disclosed
CN-115655842-B Rapid detection of alpha-dicarbonyl compounds in honey based on direct mass spectrometry technology 北京工商大学 2025-03-04 — — CN disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 — — WO disclosed
US-20100112693-A1 Differentiation of Human Embryonic Stem Cells CENTOCOR ORTHO BIOTECH, INC. 2010-05-06 — — US disclosed
WO-2010048273-A2 METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-04-29 — — WO disclosed
CN-101611152-A Methods for modulating SET and uses thereof COGNOSCI INC (US) 2009-12-23 — — CN disclosed
EP-2052085-A2 METHODS FOR MODULATING SET AND USES THEREOF Cognosci, Inc. (US) 2009-04-29 — — EP disclosed
WO-2008080082-A2 METHODS FOR MODULATING SET AND USES THEREOF COGNOSCI, INC. (US) 2008-07-03 — — WO disclosed
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 — — WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12564610-B2 Human periventricular endothelial cell therapy for neuropsychiatric disorders GABRB3, GABRB1, BMP4 MAPT 864/4885KMT2A 3024/4885MEN1 4124/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN MAPT 9/4885KMT2A 1354/4885MEN1 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback